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Abstract: Fish disease treatments have progressed significantly over the last few years  
and have moved from the massive use of antibiotics to the development of vaccines  
mainly based on inactivated bacteria. Today, the incorporation of immunostimulants and 
antigens into nanomaterials provide us with new tools to enhance the performance of 
immunostimulation. Nanoparticles are dispersions or solid particles designed with specific 
physical properties (size, surface charge, or loading capacity), which allow controlled 
delivery and therefore improved targeting and stimulation of the immune system. The use 
of these nanodelivery platforms in fish is in the initial steps of development. Here we 
review the advances in the application of nanoparticles to fish disease prevention 
including: the type of biomaterial, the type of immunostimulant or vaccine loaded into the 
nanoparticles, and how they target the fish immune system. 
Keywords: nanoparticles; fish; immunostimulation; alginate; liposome; chitosan; PLGA; 
carbon nanotubes 
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1. Introduction 
The use of vaccines has been essential in aquaculture and has been under development for over 70 
years since the first successful fish vaccine was formulated [1]. Vaccines stimulate the immune system 
to mount a defence against a pathogen and as such to protect the host from infection by this pathogen. 
While they are extremely important to control infectious diseases in farmed fish, there are still some 
hurdles affecting the development of effective vaccines against viruses, parasites, and intracellular 
pathogens. One of these bottlenecks is the vaccine administration system [2,3]. Different approaches 
have been employed in aquaculture to improve the vaccine efficacy and to explore alternative routes of 
immunization. Traditional adjuvants such as mineral oils have been routinely used for vaccine 
injection, the most common examples are Freund’s complete adjuvant (FCA), Freund’s incomplete 
adjuvant (FIA) and more recently Montanide. Although adjuvants are very effective in potentiating the 
immune response against the pathogen, they present different side effects. There are three main 
methods for vaccine administration in fish: orally, by immersion or by injection. Vaccination by 
injection is the most reliable and effective system for vaccine delivery in fish and the protection is  
by far the most effective and long lasting [4,5]. However, the injectable vaccines are usually  
prepared with oil/water adjuvant formulations (FCA or FIA) which result in adverse effects such as the 
appearance of granulomas [2,6] adhesions between organ and peritoneal wall [7], injection site  
lesions [8,9], reduced appetite and growth [10], or deformations of the skeleton [11]. Added to this, the 
anaesthesia, handling, and injection may cause occasional mortality. Importantly, there are also 
logistical challenges to inject fish of less than 20 g in large numbers, but these fish need vaccination 
the most because they are the most susceptible to disease [12]. The disadvantages of vaccination by 
immersion are: the large amounts of vaccine required [13], the difficulty to measure the efficiency of 
the uptake [14] and the degradation of the compound in the water. Like for immersion, oral vaccines 
offer the advantages of being stress free and easy to administer to large numbers of fish but it is also 
difficult to determine the dose of antigen received. Also depending whether fish are gastric or agastric 
the intact antigen has to pass through the digestive system to reach the second segment of the hindgut 
where antigens are absorbed [15,16]. In this context, the use of nanodelivery systems has been 
proposed as an alternative strategy to address not only the above mentioned problems, but also to 
enhance the efficacy since some of these delivery systems may act also as a potent adjuvant, which is 
extremely important for anti-viral vaccines. Therefore, searching for new delivery systems is required 
to improve the administration and the efficacy of vaccines and immunostimulants.  
Delivery systems are those materials used for the administration of pharmaceuticals in a controlled 
manner aimed to achieve a therapeutic effect. These systems provide: cell or tissue targeted delivery of 
active compounds, improved bioavailability, improved solubility of hydrophobic drugs, sustained 
release and protection of the therapeutic agent from degradation [17]. Nanoencapsulation involves 
forming drug loaded particles with diameters ranging from 1 to 1000 nm, although other stricter 
definitions refer only to structures in the 1–100 nm range (US National Nanotechnology Initiative, 
What is nanotechnology?). This size property enables the nanoscale devices to readily interact with 
biomolecules, such as enzymes and receptors, both on the surface and inside the cells.  
Since 1960, when the first liposomes for drug delivery were described, a variety of other organic 
and inorganic biomaterials were developed for drug delivery [17]. In 1980 more complex drug delivery 
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systems capable of responding to pH changes to trigger drug release or the first examples of cell 
specific targeting of liposomes were described [18]. Nowadays, nanoparticles can be easily tuned to 
have unique physical characteristics in size, shape, surface chemistry, or targeted surface 
ligand/receptor. The benefits of nanoparticles as delivery tools are the reduction of the doses, tissue 
specific targeting, reduction of the toxic or secondary effects of the drug and increase in the delivery 
efficiency [19]. The encapsulated molecules will generally have completely different properties (e.g., 
solubility or circulating half-life) compared to the non-encapsulated ones. Thus, it is very important to 
understand and control the in vivo behaviour on cells or tissues of these bioactive compounds once 
encapsulated, to know their efficacy and side effects. As mentioned, the size of the nanoparticle  
is not only important for the interaction with biomolecules but also because it will influence its 
biodistribution in vivo. In mammals it has been extensively studied that particles of less than 5 nm  
are cleared from the circulation through extravasation or renal clearance, whereas bigger nanoparticles 
(up to 15 μm) accumulate in the spleen, liver, and bone marrow [20]. The particle size also  
influences the preferred mechanism of cellular internalization, such as phagocytosis, macropinocytosis,  
caveolae-mediated-endocytosis, or others. Of note, the fate of the internalized material will be different 
in each case [21,22].  
In teleosts, there are few reports on how the nanoparticles spread throughout the organism through 
the circulatory system, gills, gut, spleen, liver, or brain depending on the administration route [23,24]. 
Current findings indicate that particle shape and rigidity are also key factors for the kinetics and fate of 
the nanoparticles, mainly affecting the endocytosis. The vast majority of nanoparticles have a spherical 
shape, however similar volumes with different shapes are internalized at different rates [25,26]. 
Increased nanoparticle rigidity is related to enhanced phagocytosis by macrophages [27]. Finally, the 
nanoparticle surface charge critically affects how they interact with serum proteins and cell 
membranes. Highly charged particles fix more complement proteins [28], a process that can only be 
inhibited by addition of a hydrophilic coating. The surface charge will also determine the interaction 
with cell membranes. In general, neutral and anionic nanoparticles will be less internalized than 
positively charged ones [22,29]. Different studies using the same nanoparticle with different surface 
charges have shown that those with cationic groups were internalized more efficiently, [30,31] mostly 
due to the high affinity for the negatively charged proteoglycans present on the surface of cells [32]. 
The use of nanoparticles does also have some limitations. For example, their small size and large 
surface area can lead to particle aggregation and result in limited drug loading and burst release, 
making physical handling of nanoparticles difficult in liquid and dry forms [33]. Another issue that 
should be addressed in the future is the safety, for both human and animals, not only of the delivery 
system itself but also of the degradation products of the nanoparticles. These biosafety issues should be 
carefully addressed to avoid environmental contamination that can provoke detrimental effects on 
animal and human health.  
In this review, we summarized different nano- and micro-sized delivery systems that have been 
described as delivery tools for fish vaccination or immunostimulation. Calcium phosphate nanoparticles, 
carbon nanotubes, chitosan nanoparticles, liposomes, poly-lactic-glycolic acid nanoparticles, or alginate 
micro-particles are described in detail below.  
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2. Nanodelivery Systems 
2.1. Alginate  
Alginate is found naturally in brown algae, such as Laminaria hyperborea, Laminaria digitata, 
Macrocystes pyrifera, and Lessonia nigrescens. It can also be found as a polysaccharide in some 
bacteria such as Azotobacter vinelandii and Pseudomonas [34]. Alginate is a generic name used to 
define a complex molecule made of repeated units of the unbranched polyanionic polysaccharides  
α-L-guluronic acid (G) and β-D-mannuronic acid (M). Alginate is built by combination of G-G, G-M, 
and/or M-M blocks. These blocks can be found in different G/M composition and chain arrangements, 
which gives them its differential physico-chemical properties [35,36]. The mechanical and the physical 
stability of alginate mainly depend on the G content, the greater the G content, the more rigid and 
brittle the matrix [37]. Alginate-microparticles (alginate-MPs) are eroded at neutral and basic pH 
allowing the release of the cargo by diffusion, while at low pH values they are extremely stable [38]. 
This stability at low pH makes alginate-MPs suitable for oral administration, since in the fish stomach 
(pH between 2 and 4) the release will be low while the release in the foregut or hindgut at neutral-basic 
pH (pH 7 and 8.3, respectively) will be high [39,40]. Notably, alginate is mucoadhesive allowing the 
adhesion to the epithelial mucus (e.g., intestinal mucosa) and making it very attractive for oral 
administration. Other important features of alginate-MPs are the high biocompatibility and the low 
cost of production.  
Alginate-MPs can be produced by classical techniques such as air atomization, emulsification, 
gelation, and complexation with counterion polymers, or by new methods, such as spray-drying, 
electrohydrodynamic atomization, impinging aerosols, and inkjet/drying process, that enable a  
better control of the size [37]. For application in fish, alginate-MPs are generally produced by  
emulsification [39–42] that is one of the fastest methods for nanoparticle preparation and is readily 
scalable [43], and to a lesser extent by other methodologies such as the orifice-ionic gelation and the 
spray method [44,45] (Table 1).  
In mammals, alginate nanoparticles have been used for the delivery of different drugs [46–49], but 
to date there are no alginate nano-sized particles routinely used for delivery of active compounds in 
fish. Nevertheless, micro-sized alginate particles are one of the most common delivery systems 
assayed in fish with promising results for viral diseases.  
2.1.1. Encapsulation of Bacterial Antigens in Alginate Microparticles 
To date, the main bacterial antigens encapsulated into alginate-MPs have been formalin-killed 
bacteria (FKB) from different species (Table 1). FKB have been widely used as antigens for fish 
vaccination in some diseases, mainly those caused by Gram-negative bacteria. In general, FKB 
vaccines provide excellent levels of protection by itself or in combination with an adjuvant  
(e.g., FCA) [40,50]. In general, oral administration of FKB encapsulated in alginate-MPs does not 
work very well alone, and only when combining the alginate-MPs with the FKB vaccine they obtained 
a longer lasting protection. The oral administration of alginate-FKB from Lactococcus garviaeae in 
rainbow trout (Oncorhynchus mykiss) provided low levels of protection against L. garviaeae infection 
(35% Relative percent survival (RPS) at 30 days) compared with the naked FKB vaccine administrated 
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intraperitoneally (100% RPS at 30 days and 40% at 90 days) (Table 1). These results were improved 
when fish were immunized orally a second time with the alginate-vaccine three months later (61% RPS at 
180 days) [44]. Altun and coworkers observed similar result with this alginate-construct administrated 
orally in rainbow trout (Table 1). It did not provide better protection against L. garviaeae infection 
(53% RPS at 30 days and 38% RPS at 60 days) than the naked vaccine (95% RPS at 30 days and 82% 
RPS at 60 days). The protection was again increased when fish was immunized a second time with 
alginate-FKB-LG at day 61 (67% RPS at 90 days and 62% RPS at 120 days) or with a first 
administration of naked vaccine and then a second administration of the alginate-construct at day 61 
(86% RPS at 90 days and 81% RPS at 120 days) [45].  
Leal et al. [40] evaluated the alginate-MPs formulated with FKB from Flavobacterium columnare 
in nile tilapia (Oreochromis niloticus) (Table 1). Alginate-vaccine and naked vaccine administrated 
orally did not provide protection against F. columnare challenge (0% of RPS at 21 days in both cases) 
and did not stimulate the production of specific antibodies against F. columnare in immunized fish [40].  
2.1.2. Encapsulation of Viral DNA in Alginate Microparticles 
For viral diseases, alginate-MPs have been used to encapsulate DNA vaccines made with plasmids 
coding for viral proteins. The alginate-MPs loaded with DNA vaccines are smaller (≤ 10 µm) than the 
alginate-MPs loaded with bacterial antigens (10–30 µm) [44] and this seems to favor the targeting of 
different organs, such as spleen, kidney, liver, pyloric caeca, heart, intestine, or gills [41,42].  
Alginate-MPs containing the plasmid coding for the major capsid protein (MCP) of Lymphocystis 
Disease Virus (LCDV) increased the titer of specific antibodies against LCDV in olive flounder 
(Paralichthys olivaceus) serum after oral administration (Table 1). The results showed a progressive 
increase until week 11 while the naked DNA vaccine did not stimulate any increase in the  
antibody titer. The naked DNA vaccine might thus be hydrolyzed in the gastrointestinal tract while the  
alginate-MPs can reach the tissues [41].  
Alginate-MPs with a plasmid coding for VP2, one of the major structural proteins of Infectious 
Pancreatic Necrosis Virus (IPNV) stimulated the production of specific neutralizing antibodies in  
O. mykiss until eight weeks after oral administration (Table 1). In infection experiments with this virus, 
alginate-MPs orally administrated to O. mykiss and Salmo trutta increased the protection levels nearly 
to 80% RPS at 15 and 30 days post-vaccination [42]. These levels of protection were comparable with 
a commercial subunit vaccine (e.g., Microtek) administrated by intraperitoneal injection [51].  
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Table 1. Microparticles used as delivery systems in fish. 
Microparticle Size  
Production Technique  
and Composition 
Encapsulated Molecule Administration Species Fish Size RPS Reference 
Alginate 30 µm  
Spray method,  
sodium alginate, 0.5% (w/v) 
FKB from 
Lactococcus garviaeae 
Oral 
Onchorhynchus 
mykiss 
22 g 
35% E and 100% N at 30 DPV; 5% E and 
40% N at 90 DPV; 61% first V with N and 
second with E at 180 DPV 
[44] 
 
n.d. 
Orifice-ionic gelation, 
Sodium alginate, 4% (w/v) 
FKB From 
Lactococcus garviaeae 
Oral 
Onchorhynchus 
mykiss 
20 g 
53% E and 95% N at 30 DPV; 38% E and 
82% at 60 DPV; 67% first V with N and 
second with E at 90 DPV; 62% first and 
second V with E at 120 DPV 
[45] 
 
n.d. 
Emulsification,  
sodium alginate, 3.5% (w/v) 
FKB from  
Flavobacterium columnare 
Oral 
Oreochromis 
niloticus 
15.7 g 0% E and 0% N at 21 DPC [40] 
 
≤ 10 µm  
Emulsification,  
sodium alginate, 3% (w/v) 
Plasmid DNA: MCP from 
LCDV 
Oral 
Paralichthys 
olivaceus 
40–60 g n.d. [41] 
 
10 µm 
Emulsification,  
sodium alginate, 3% (w/v) 
Plasmid DNA: VP2 from 
IPNV 
Oral Salmo trutta 1.5 g/3 cm 
At 15 DPV: 78% E and 0% empty plasmid 
at 30 DPC, At 30 DPV: 79% and 0% 
empty plasmid at 30 DPC (*) 
[42] 
 
10 µm 
Emulsification,  
sodium alginate, 3% (w/v) 
Plasmid DNA: VP2 from 
IPNV 
Oral 
Onchorhynchus 
mykiss 
1 g/3.5 cm 
At 15 DPV: 80% E and 5% empty plasmid 
at 30 DPC; At 30 DPV: 67% and 0% 
empty plasmid at 30 DPC (*) 
[42] 
Chitosan ≤ 10 µm 
Emulsification,  
3% chitosan (m/v) 
Plasmid DNA: MCP from 
LCDV 
Oral 
Paralichthys 
olivaceus 
50–100 g 
and  
13–15 cm 
n.d. [52] 
 < 5 µm 
Spray drying, 240 mg of 
PVMMA and 250 mg of 
chitosan Seacure 210 HCl 
Surface antigens (Ag) 
from Philasterides 
dicentrarchi 
i.p. injection 
Scophthalmus 
maximus 
50 g 
68% E, 58% Ag in FCA and 43% FCA at 
20 DPC 
[53] 
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Table 1. Cont. 
Microparticle Size  
Production Technique  
and Composition 
Encapsulated 
Molecule 
Administration Species Fish Size RPS Reference 
Chitosan 
4.28 ± 0.4 
µm 
Spray drying, 240 mg of 
GantrezAN119 and 250 mg 
of chitosan Seacure 210 HCl 
Surface antigens (Ag) 
from Philasterides 
dicentrarchi 
In vitro,  
anterior kidney 
leukocytes 
Scophthalmus 
maximus 
n.d n.d. [54] 
 
1.101 ± 
0.0103 µm  
TPP ionic gelation,  
5 mg/mL chitosan in 
sodium alginate solution at 
concentration of 10 mg/mL 
FKB from  
Aeromonas hydrophila 
Oral  Labeo rohita Juveniles 
13% alginate and chitosan E,  
13% chitosan E, 16% alginate and 
chitosan, 0% N at 15 DPC (*) 
[55] 
PLGA 1.12 µm  
D.E., PLGA 50:50,  
MW: 30–70 kDa 
OMP from  
Aeromona hydrophila 
Parenteral Labeo rohita 
30–40 g and  
250–300 g 
n.d. [56] 
 
< 10 µm  
D.E., L:G = 75:25,  
MW:50 kDa 
Plasmid DNA: MCP 
from LCDV  
Oral 
Paralichthys 
olivaceus 
500–1000 g n.d. [57] 
 
1 µm Emulsion, PLGA 50:50 
γ-globulins from 
human blood 
Oral 
Onchorhynchus 
mykiss 
100–200 g n.d. [58] 
 
n.d. D.E., PLGA 50:50 
i-antigen from 
Uromena marinum 
i.p. injection 
Epinephelus 
bruneus 
31.4 ± 2.3 g  78% E and 66% N at 30 DPC (*) [59] 
PLGA/Liposome 5–10 µm 
Film dispersion method, 
PS, PC, and Chol  
(molar ratio 1:10:5) 
FKB from  
Aeromonas hydrophila 
Oral Cyprinus carpio 30 g 64% E at 12 DPC [60] 
 
n.d. D.E., PLGA 50:50 ODN1668 i.p. injection 
Epinephelus 
bruneus 
36.7 ± 2.8 g  
78% PLGA E, 83% Liposome E, 
83% PLGA/Liposome E and 78% 
N at 30 DPC (*) 
[61] 
Chol: Cholesterol; D.E.: double emulsion; DPC: days post-challenge; DPV: days post-vaccination; E.: encapsulated antigen; FCA: Freund’s complete adjuvant; FKB: formalin killed 
bacteria; GantrezAN119: methyl vinyl ether-co-maleic anhydride; i.p.: intraperitoneal; IPNV: Infectious pancreatic necrosis virus; MCP: major capsid protein; N: naked antigen; n.d.: not 
described; LCDV: Lymphocystis disease virus; ODN1668: oligodeoxynucleotide 1668; Omp: outer membrane protein; PC: Phosphatidylcholine; PLGA: poly(lactic-co-glycolic acid); PS: 
Phosphatidylserine; PVMMA: Poly (methyl vinyl ether)-co-(maleic anhydre); RPS: Relative percent survival; V: vaccination; VP2: Viral protein 2; (*): calculated RPS. 
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2.2. Carbon nanotubes  
Carbon nanotubes (CNTs) were discovered in 1991 by Iijima [62]. CNTs are allotropes of carbon 
with a cylindrical nanostructure and this network of carbon atoms can reach several micrometers in 
length with a nanosized diameter. CNTs can be produced at large scale by three methods: discharge, 
laser ablation, and chemical vapor deposition. During the production process with all these methods 
impurities are formed, thus requiring an additional purification step [63]. Pure CNTs are not soluble in 
aqueous solutions because they have highly hydrophobic surfaces and an additional functionalization 
step is needed. There are two main types of carbon nanotubes, single-walled, and multi-walled.  
Single-walled CNTs are flexible but require catalytic synthesis making its bulk production difficult and 
leading to poor levels of purity. Multi-walled CNTs are formed by several concentric layers and  
thus are more rigid. They can be produced without catalyst, which allows bulk synthesis and  
high purity [64]. CNTs are chemically stable, relatively inert, non-immunogenic, and non-toxic. 
Additionally, CNTs have a large surface area available and are able to absorb or to be conjugated to a 
wide variety of antigens, presenting high stability in vivo [65,66]. In mammals, CNTs are being 
investigated as a delivery system for genes, peptides, oligonucleotides, antimicrobial agents, and 
cytotoxic drugs [67–70]. In fish, the study of CNTs as delivery systems has recently started, focusing 
on its functionalization with chemical groups and proteins and on the encapsulation of DNA  
vaccines [71–73] (Table 2).  
2.2.1. Functionalization of CNTs 
As mentioned above, functionalization is required to solubilize the CNTs and to make them 
biocompatible. This process can be divided in two different approaches, depending on the  
covalent/non-covalent nature of the linked antigens [64]. The covalent attachment of different chemical 
groups (e.g., sulfonate) and proteins (e.g., bovine serum albumin) has been used to design nanoparticles 
for fish [71–73]. Different studies warn about the potential for these manufactured nanomaterials to 
contaminate the aquatic environment. To evaluate immunotoxicity, functionalized single-walled and 
multi-walled CTNs with chemical groups, such as sulfonate, sulfonic acid, and polyethylene glycol were 
tested for toxicity in head kidney macrophages isolated from O. mykiss (Table 2). The CNTs 
formulations did not decrease the cell viability after 24 h treatment [72]. None of these formulations 
stimulated the expression of interferon alpha (IFNα) gene, however CNTs with and without 
functionalization stimulated interleukin 1 beta (IL-1β) gene expression in trout macrophages indicating 
that they can be pro-inflammatory if they gain entry to the body. Multi-walled CNTs containing anionic 
groups (sulfonate groups) caused the highest IL-1β stimulation, while single-walled CNTs containing 
neutral groups (polyethylene glycol groups) caused the least reaction. The functionalized CNTs were 
also more potent in stimulating gene expression than the non-functionalized counterparts [72]. 
The functionalized CNTs thus produce a stimulation of the immune system by themselves without 
any loaded antigen [71,72], although there is no information about the levels of protection that they 
may provide in a challenge. Fluorescent multi-walled CNTs functionalized with bovine serum albumin 
(BSA) were tested in zebrafish (Danio rerio) embryos by microinjection into the circulation at 72 h 
post fertilization (Table 2). These CNTs distributed all along the blood circulation and then moved to 
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the muscle, brain ventricle and notochord, being finally cleared out at 96 h after injection. The immune 
response of the embryos was studied by in situ hybridization of Matrix Metalloproteinase 9 (MMP9). 
At early stages, the injected embryos showed an increase in MMP9 expression levels and changes in 
the expression pattern. These results suggest that embryos may generate an innate immune response 
when being injected with CNTs at the 1-cell stage. The injected zebrafish embryos had normal 
primordial germ cells and were able to produce a new generation at the adult stage. However, the 
larvae of the second generation showed lower survival rates as compared with the untreated group, 
suggesting a negative effect on the reproduction potential [71]. 
2.2.2. Encapsulation of Viral DNA in CNTs 
To date only one work has evaluated CNTs as a DNA delivery system in fish, but with promising 
results. Single-walled CNTs were loaded with a plasmid encoding the VP7 protein of Grass Carp 
Reovirus (GCRV). The plasmid expression after intramuscular injection in grass carp 
(Ctenopharyngodon idella) was detected at high levels in muscle at 28 days post-injection. At the level 
of the humoral response, specific VP7 antibody production was detected during eight weeks with a 
peak titer at four weeks post-vaccination. Other immune parameters such as respiratory burst, serum 
lysozyme activity, complement activity, or superoxide dismutase activity were also stimulated. 
Importantly, in a challenge against GCRV, the treated fish showed good protection levels even at low 
plasmid doses (1 µg: 73% RPS, 5 µg: 91% RPS and 10 µg: 100% RPS) when compared with the 
naked plasmid (1 µg: 9% RPS, 5 µg: 27% RPS and 10 µg: 44% RPS) [73] (Table 2). 
2.3. Chitosan 
Chitin is a natural, biodegradable, biocompatible, and nontoxic biopolymer derived from the shells 
of crustaceans, insects, and some microorganisms. It can be converted to chitosan, a linear 
polysaccharide compound of β-(1-4)-linked D-glucosamine and N-acetyl-D-glucosamine obtained from 
the N-deacetylated derivative of chitin by enzymatic or chemical processes. Chemical methods are 
used extensively for chitosan preparation for commercial purposes because of their low cost and 
scalability, but have a high energetic cost and produce a concentrated alkaline waste solution. In 
contrast, enzymatic methods offer the possibility of a controlled process, resulting in the production of 
well-defined chitosan [74]. Chitosan nanoparticles are prepared by ionic gelation [75], followed by 
freeze-drying (or spray-drying) to recover these particles.  
The solubilization of chitosan occurs by protonation of the -NH2 group on the C-2 position of the  
D-glucosamine repeat unit, whereby the polysaccharide is converted to a polyelectrolyte in acidic 
media. Being soluble in aqueous solutions, chitosan and its derivatives are largely used in medical and 
pharmaceutical applications like artificial matrices for tissue engineering, targeted drug delivery, drug 
transport, protein delivery or gene transfer [76–79]. They can be functionalized to display antimicrobial 
activity against many bacteria, filamentous fungi and yeasts [80], hemostatic potential [81], and 
antioxidant activity [82]. 
The beneficial applications of chitosan on fish have been demonstrated in different studies in which 
chitosan nanoparticles were administrated through diet. Diets supplemented with chitosan for rainbow 
trout [83], olive flounder [84], koi [85], kelp grouper [86], turbot [87], gibel carp [88], mrigal  
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carp [89], and Asian seabass [90] have proved that the chitosan could enhance growth, the innate 
immunity, disease, and stress resistance, improve haematological parameters and improve water 
quality. From fish immunological perspective, chitosan nanoparticles have been used for the delivery 
of vitamin C [91], RNA [92], or DNA [93–95] due to their positive charge and solubility in aqueous 
solution. In addition, chitosan protects encapsulated active compounds from the harsh conditions in the 
gastrointestinal tract and enhances their absorption [96]. Therefore, chitosans can be used for 
delivering immunostimulants or vaccines to fish in aquaculture. 
2.3.1. Encapsulation of Compounds in Chitosan Nanoparticles 
The DNA that encodes for the 38 kDa protein of the external membrane (OMP38) of Vibrio 
anguillarum was encapsulated in chitosan and administered with food to Asian sea bass (Lates 
calcarifer). It induced a significant antibody immune response and was able to give moderate levels of 
protection (RPS 46%) against experimental challenge with V. anguillarum [94] (Table 2). Another 
pDNA vaccine constructed with the outer membrane protein K of Vibrio parahaemolyticus was 
encapsulated in chitosan nanoparticles and mixed with dry fish food powder and used to feed 
blackhead seabream (Acanthopagrus schlegelii). The outer membrane protein K gene and protein were 
expressed in muscle, liver, kidney, and mid-intestine of the vaccinated animals. Furthermore, 
blackhead seabream were protected from V. parahaemolyticus challenge with 72.3% RPS after 21 days 
post-vaccination [95] (Table 2). Ramos and coworkers also clearly showed that chitosan is an excellent 
DNA delivery system through oral administration, either by feeding with plasmid DNA-chitosan 
incorporated into the food, or by direct intrabuccal delivery [93] (Table 2).  
In a different setup, dietary RNA (i.e., nucleotides derived from yeast) was loaded into chitosan 
nanoparticles at a chitosan/RNA ratio of 2:1 and were fed during 60 days to fingerlings of Labeo 
rohita. The body composition in terms of protein and lipid content was not affected by RNA-loaded 
chitosan nanoparticles (chitosan-NPs) while the growth, performance, immunity, and survival 
following a bacterial challenge (Aeromonas hydrophila) were significantly increased compared to only 
chitosan or bare RNA. Unaffected glucose and serum uric acid levels, and decreased transaminases 
and dehydrogenases, coupled with improved performance, indicated an enhanced energetic efficiency 
for anabolic processes and the safety of RNA-loaded chitosan-NPs as a nutraceutical [92] (Table 2). 
Finally, chitosan-NPs are very suitable to encapsulate Vitamin C. In the gastrointestinal tract of 
rainbow trout (O. mykiss), the release of Vitamin C was regulated by the chitosan encapsulation up to 
48 h. The innate immunity indices (lysozyme and complement proteins) were considerably increased 
in the treated rainbow trout and even the non-specific defense mechanisms were stimulated as a result 
of the synergistic effects caused by Vitamin C and the chitosan nanoparticle itself [91] (Table 2). 
Vitamin C was also administered in this way to post-metamorphic larvae of Solea senegalensis and 
rotifers (Brachionus plicatilis). The NPs were stable in seawater and in vitro assays with a zebrafish 
liver cell-line showed a statistically significant increase in total antioxidant capacity. In addition, the 
nanoparticles were able to penetrate through the intestinal epithelium in S. senegalensis larvae and 
could be used as an enriching additive for rotifers [97] (Table 2). 
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2.3.2. Encapsulation of Compounds in Chitosan Microparticles 
Not only chitosan-NPs but also the larger chitosan microparticles (chitosan-MPs) are intensively 
studied. A plasmid containing the major capsid protein (MCP) gene of Lymphocystis Disease Virus 
(LCDV) was encapsulated in chitosan-MPs using an emulsion-based methodology. Oral administration 
led to an increase in the immune response in Japanese flounder (Paralichythys olivaceus) compared to 
injection immunization with naked plasmid DNA [52] (Table 1). The surface antigens (Ag) of the 
parasite Philasterides dicentrarchi were encapsulated and covalently linked to a polymeric microparticle 
formulation composed of two biodegradable polymers (chitosan and Gantrez). Poly (methyl vinyl 
ether)-co-(maleic anhydride) (Gantrez AN119) is a polymer belonging to the vinyl ether group that it is 
widely used for pharmaceutical purposes and has also been used to prepare ligand-nanoparticle 
conjugates for eliciting immune responses [98]. These chitosan and gantrez MPs encapsulated vaccine 
induced higher level of antibody than that induced by the same vaccine emulsified in FCA [53] (Table 1). 
These MPs could also significantly stimulate the phagocytic activity of leukocytes and the levels of the 
pro-inflammatory cytokine tumor necrosis factor alpha (TNFα) and also increased the production of 
reactive oxygen and nitrogen species in the anterior kidney of turbot (Scophthalmus maximus) [54] 
(Table 1). Finally, alginate-coated chitosan-MPs were evaluated through oral dietary administration.  
A potent humoral and innate immune response was elicited but it was not sufficient to induce 
protection against Aeromonas hydrophila infection under these conditions [55] (Table 1).  
2.4. Liposomes 
Liposomes are spherical, closed structures, composed of phospholipid bilayers, which enclose part 
of the surrounding solvent into their interior [99]. They are self-sealing and have the capacity to 
incorporate both hydrophilic and lipophilic drugs. Since the early 1980s, liposomes have been 
extensively studied as a drug carrier transport to target cells or tissues [100–103]. The drug delivery 
properties of liposomes are largely determined by factors such as the lipid composition, the particle 
size, the net charge and the loaded compound [104]. The liposome charge needs to be considered when 
administering molecules to fish, since fish gills contain a high level of mucin. In rainbow trout fry, a 
mechanism of acute toxicity after liposome treatment was suggested to be an interaction between the 
cationic liposomes and anionic components of gill mucin [105]. However, no toxicity was reported in 
zebrafish after immersion administration of nanoliposomes [23]. 
There is a wide variety of techniques that can be used to produce liposomal formulations, such as 
the Bangham method, detergent depletion method or extrusion [106]. All methods for producing 
liposomes require lipids to be combined by some means with an aqueous phase [107]. The extrusion 
technique is the most common method to prepare liposomes because it allows a better control of the 
size and the polydispersity index [108,109]. Extrusion is a process in which micrometric liposomes are 
structurally modified to large unilamellar vesicles or nanoliposomes depending on the pore-size of the 
filters used [108,110,111]. Compared to micro-liposomes, nanoliposomes provide more surface area 
and have the potential to increase solubility, enhance bioavailability, improve controlled release, and 
enable precision targeting of the encapsulated material to a greater extent [112]. 
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2.4.1. Encapsulation of Bacterial Antigens in Liposomes 
FKB vaccines composed of liposomes entrapping Vibrio harveyi were tested in Epinephelus bruneus. 
In in vivo infection assays, the cumulative mortality was 10%, 15%, and 65% lower in this immunized 
group compared to treatment with V. harveyi alone, liposome alone and non-immunized groups, 
respectively [113] (Table 2). In another study in carp (Cyprinus carpio), the oral administration of 
liposomes containing Aeromonas salmonicida antigen was investigated. The survival of carp after the 
challenge was 83% when they were immunised with A. salmonicida antigen-containing liposomes, 
whereas non-immunized carp showed 66% survival. Furthermore, the development of skin ulcers was 
significantly inhibited in carp immunized with liposomes containing A. salmonicida antigen [114].  
Lipopolysaccharide (LPS) from A. salmonicida was also incorporated into liposomes in order to 
enhance the immune response in rainbow trout (O. mykiss). LPS incorporated into multilamellar 
vesicles or large unilamellar vesicles prolonged the period of serum anti-LPS antibody levels to 6–14 
weeks comparing to free-LPS (2–4 weeks) when administered intraperitoneally [115] (Table 2). Also 
in rainbow trout, the immune efficacy of vaccine containing liposome particles with vaccine alone 
against furunculosis was compared [116]. Results indicated that the protection level was significantly 
enhanced when the vaccine also contained liposomes (Table 2). In addition, vaccinated fish appeared 
to be significantly larger than control fish.  
Lastly, the A. hydrophila antigens entrapped in liposomes were developed for oral administration to 
immunize common carp (C. carpio). The levels of antibodies in the serum rose at two and three weeks 
post-vaccination and the vaccination protected the fish after injection with live A. hydrophila at 22 
days post-vaccination [60] (Table 2). 
2.4.2. Encapsulation of Viral Antigens in Liposomes 
Formalin-inactivated koi herpesvirus entrapped within liposomes was used for oral vaccination of 
common carp (C. carpio). Specific antibody titer was significantly increased and challenge experiments 
revealed that orally vaccinated fish were protected from infection with two different isolates of koi 
herpesvirus (NKC03 and IKC03) showing high RPS (75% and 65%, respectively) [117] (Table 2). 
Distinct from classical vaccines, immunostimulant-loaded liposomes are also developed to protect 
fish against bacterial and viral infections. For example, polyinosinic-polycytidylic acid (Poly I:C) is a 
synthetic analog of double-stranded RNA and is a typical molecular pattern associated with viral 
infections. When combined with LPS, it is a strong stimulus to the innate immune system. Liposomes 
encapsulating both Poly I:C and LPS elicited a pro-inflammatory and anti-viral response in zebrafish 
hepatocytes and trout macrophages. When administrated in vivo they accumulated in immune tissue 
and specifically in macrophages. Of interest, they protected zebrafish against otherwise lethal bacterial 
(Pseudomonas aeruginosa PAO1) and viral (Spring Viraemia of Carp Virus) infections regardless of 
whether they were administered by injection or by immersion. No stimulation of innate immunity was 
observed in the treatment with empty liposomes or with the free immunostimulants [23,118] (Table 2). 
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Table 2. Nanoparticles used as delivery system in fish. 
Nanoparticle Size 
Production Technique  
and Composition 
Encapsulated 
Molecule 
Administration Species Fish Size RPS Reference 
Calcium 
phosphate 
224.98 ± 14.62 
nm 
n.d. 
S-layer protein from  
Aeromonas hydrophila 
i.p. injection Labeo rohita 
100–150 
g 
97% E, 13% N and 94% E with 
FIA at 15 DPC (*) 
[119] 
Carbon 
nanotubes 
d: 10-20 nm;  
l: 1–2 µm 
n.d., SWCNTs and MWCNTs 
Sulfonate group, 
polyethyleglycol  
and sulfonic acid 
In vitro, head 
kidney 
monocytes  
Oncorhynchus 
mykiss 
0.5–1 kg n.d. [72] 
  
d: 19.9 ± 8.25 nm; 
l: 0.8 ± 0.5 µm 
n.d., MWCNTs BSA Microinjection Danio rerio 
embryos/
larvae 
n.d. [71] 
 
n.d. n.d., SWCNTs 
Plasmid DNA: VP7 
from grass carp 
reovirus 
i.p. injection 
Ctenopharyngodon 
idella 
25–30 g 
73% E (1 µg), 91% E (5 µg) 
100% E (10 µg), 9% N (1 µg), 
27% N (5 µg) and N (10 µg) at 15 
DPC  
[73] 
Chitosan n.d. 
0.02% chitosan in sodium acetate 
buffer 
Plasmid DNA: OMP38 Oral  
Lates 
calcarifer 
Juveniles 46% E at 14 DPC [94] 
 
218.9 nm 
TPP ionic gelation, 2 mg/mL 
chitosan in 3% (v/v) acetate 
Plasmid DNA: OMPK Oral  
Acanthopagrus 
schlegelii 
15–16 
cm  
72.3% E and 0% N 14 DPC [95] 
 
n.d. 
Complex coacervation,  
0.02% (w/v) powdered chitosan 
Plasmid DNA: 
βgalactosidase 
Oral  
Oreochromis 
niloticus 
5–10 cm 
and  
33–40 g  
n.d. [93] 
 
287.1 ± 1.49 
nm 
Complex coacervation, chitosan to 
RNA ratio: 1:1, 2:1, and 3:1 
Bare RNA Oral  Labeo rohita 2.7–3.1 g 
83% E (2:1) and  
33% N at 15 DPC (*) 
[92] 
 
185.4 ± 2.1 nm 
TPP ionic gelation, chitosan in  
1% (w/v) acetic acid solution 
Vitamin C Oral  
Onchorhynchus 
mykiss 
Adult n.d. [91] 
 
253–258 nm 
Ionotropic gelation, chitosan at 
concentration of 
2.4 mg/mL in acetic acid solution 
(0.4% v/v) 
Vitamin C Oral 
Solea 
senegalensis 
Larvae n.d. [97] 
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Table 2. Cont. 
Nanoparticle Size 
Production Technique 
and Composition 
Encapsulated 
Molecule 
Administration Species Fish Size RPS Reference 
Liposomes n.d. 
Film dispersion method. DPPC, 
DPPS, Chol (molar ratio 1:10:5) 
FKB Vibrio harveyi  i.p.injection 
Epinephelus 
bruneus 
29.5 ± 2.1 g 
75% E, 65% N and 60% 
liposome at 30 DPC 
[113] 
 
n.d. 
Film dispersion method. DPPC 
(0.5 µmol), DPPS (0.5 µmol) and 
Chol (1 µmol) 
Aeromonas 
salmonicida  
total extract 
Oral 
Cyprinus 
carpio 
350 g 54% E at 30 DPC (*) [114] 
 
200 nm 
Extrusion method. PC:Chol: PG 
or PC:Chol:SA in a 6:3:1  
molar ratio 
LPS from Aeromonas  
salmonicida 
i.p.injection 
Onchorhynchus 
mykiss 
40 and 80 g n.d. [115] 
 
n.d. 
Film dispersion method.  
600 mg of phosphatidylcholine in 
25 mL chloroform  
FKB Aeromonas 
salmonicida, 
inactivated toxin and 
LPS 
Immersion 
Salmo 
gairdneri 
Fry 
70% E and 59% N at  
126 DPC (*) 
[116] 
 
n.d. 
Film dispersion method. PS, PC, 
and Chol (molar ratio 1:10:5) 
Koi herpesvirus whole 
extract 
Oral 
Cyprinus 
carpio 
30 g 
74% E (NKC03) and 65% E 
(IKC03) at 23 DPC 
[117] 
 
125 nm 
Extrusion method. DOPA, DLPC, 
Chol, Cholesteryl and  
Chol-PEG600 
LPS and Poly I:C 
In vitro, zebrafish 
hepatocytes and 
head kidney 
macrophages 
Danio rerio 
and 
Onchorhynchus 
mykiss 
Zebrafish 
hepatocytes, 
trout 
macrophages 
n.d. [118] 
  125 nm 
Extrusion method. DOPA, DLPC, 
Chol, Cholesteryl and  
Chol-PEG600 
LPS and Poly I:C 
Injection and 
immersion 
Danio rerio Adult 
33% E, 21% N and 20% 
liposome at 15 DPC 
[23] 
 
n.d. 
High-pressure homogenization. 
6% (wt/v) cinnamaldehyde,  
10% (v/v) lecithin and 0.5% (v/v) 
α-tocopherol 
Cinnamaldehyde Immersion Danio rerio Adult 
58% E at 11 DPC (Vibrio 
Vulnificus), 35% E at 8 DPC 
(Aeromonas hydrophila) and 
31% E at 8 DPC 
(Streptococcus agalactiae) (*) 
[120] 
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Table 2. Cont. 
Nanoparticle Size 
Production Technique 
and Composition 
Encapsulated 
Molecule 
Administration Species Fish Size RPS Reference 
Liposome n.d. 
Lipid film hydration, lipid:peptide 
ratio of 1:50 
Melittin 
In vitro, EPC cell 
line  
Pimephales 
promelas  
EPC cell 
line  
n.d. [121] 
 
n.d 
Film dispersion method, DPPC 
(0.5 µmol), DPPS (0.5 µmol) and 
Chol (1 µmol), or DPPC  
(3.5 µmol) and Chol (1 µmol) 
BSA Oral 
Cyprinus 
carpio 
350 g n.d. [122] 
PLGA 125–225 nm 
D.E., PLGA: 50:50 (40–75 kDa); 
PLA (85–160 kDa)  
OMP from Aeromonas 
hydrophila 
i.p. injection Labaeo rohita 50 ± 10 g 
75% PLA, 55% PLGA and  
38 % N at 42 DPV 
[123] 
 
320–500 nm D.E., n.d. 
Plasmid DNA: Firefly 
luciferase gene 
i.m. injection Salmo salar 30 g n.d. [124] 
 
< 500 nm D.E., n.d. 
Plasmid DNA: MCP 
from LCDV 
Oral 
Paralichthys 
olivaceus 
50–100 g n.d. [125] 
 
n.d. 
D.E., 5% of PLGA/methylene 
chloride and 5% of PVA/water 
soluble 
Plasmid DNA:  
protein-G from IHNV 
Oral 
Onchorhynchus 
mykiss 
5 g 
11% E low dose, 22% E high 
dose and 82% N at 180 DPC; 0% 
E low dose, 19% E high dose and 
55% N at 300 DPC 
[126] 
 
300–400 nm 
D.E., PLGA : 50:50 (5–15 kDa; 
40–75 kDa); 75:25 (66–107 kDa); 
PLA (24–47 kDa)  
Hemocyanin from 
Limulus polyphemus 
i.p. injection Salmo salar 29 ± 3.1 g n.d. [127] 
  300–400 nm 
D.E., PLGA: 50:50 (5–15 kDa; 
40–75 kDa); 75:25 (66–107 kDa); 
PLA (24–47 kDa)  
β-glucan i.p. injection Salmo salar 29 ± 3.1 g n.d. [127] 
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Table 2. Cont. 
Nanoparticle Size 
Production Technique 
and Composition 
Encapsulated 
Molecule 
Administration Species Fish Size RPS Reference 
PLGA  300–400 nm 
D.E., PLGA: 50:50 (5–15 kDa;  
40–75 kDa); 75:25 (66–107 kDa); 
PLA (24–47 kDa)  
β-glucan i.p. injection Salmo salar 29 ± 3.1 g n.d. [127] 
  < 1000 nm D.E., n.d. 
γ-globulins from human 
blood 
i.p. injection Salmo salar 30 g n.d. [128] 
  < 1000 nm D.E., n.d. β-glucan i.p. injection Salmo salar 30 g n.d. [128] 
SLN 141–335 nm n.d. 6-Coumarin 
In vitro, SAF-1 
cell line and HK 
leukocytes 
Sparus aurata 100 g n.d. [129] 
BSA: Bovine serum albumin; Chol: Cholesterol; D.E.: double emulsion; DLPC: 1,2-didodecanoyl-sn-glycero-3-phosphocholine; DOPA: 1,2-dioleoyl-sn-glycero-3-phosphoric acid 
monosodium salt; DPC: days post-challenge; DPPC: Dipalmitoylphosphatidylcholine; DPPS: Dipalmitoylphosphatidylserine; E: encapsulated antigen; FIA: Freund`s incomplete adjuvant; 
FKB: formalin killed bacteria; i.m.: intramuscular injection; i.p.: intraperitoneal; IHNV: Infectious haematopoetic necrosis virus; LCDV: Lymphocystis disease virus; LPS: 
Lipopolysaccharide; MCP: major capsid protein; MWCNTs: Multi-Walled Carbon Nanotubes; N: naked antigen ; n.d.: not described; NKC03 and IKC03: two koi herpesvirus isolates; OMP: 
outer membrane protein; OMP38: outer membrane protein of Vibrio anguillarum; OMPK: Outer membrane protein K; PC: Phosphatidylcholine; PG: Phosphatidylglycerol; PLA: Polylactic 
acid; PLGA: poly(lactic-co-glycolic acid); Poly I:C: Polyinosinic:polycytidylic acid; PS: Phosphatidylserine; PVA: polyvinyl alcohol ; RPS: Relative percent survival; SA: Stearylamine; 
SWCNTs: Single-Walled Carbon Nanotubes; βgal: β-galactosidase; VP7: Viral protein 7; (*): calculated RPS. 
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2.4.3. Encapsulation of Other Compounds in Liposomes 
Cinnamaldehyde, a natural compound extracted from cinnamon, was encapsulated in liposomes. 
These liposomes displayed antimicrobial activity in vitro against aquatic pathogens such as 
Streptococcus agalactiae, Aeromonas hydrophila, and Vibrio vulnificus, as well as the antibiotic 
resistants Vibrio parahaemolyticus and Vibrio alginolyticus. The in vivo results using an immersion 
treatment demonstrated an increased survival rate and bacterial growth inhibition in zebrafish infected 
with S. agalactiae, A. hydrophila and V. vulnificus [120] (Table 2).  
Also melittin, an antimicrobial peptide, was loaded into liposomes with covalently attached 
antibodies directed against Viral Haemorrhagic Septicemia Rhabdovirus (VHSV) glycoprotein G 
(Table 2). These melittin-immunoliposomes were capable of inhibiting the VHSV infectivity by 95% 
via direct inactivation of the virus. To our knowledge, this is the first report on fish pathogen targeted 
liposomes. However, the characterization of this formulation was not described nor the size or the 
charge of this formulation [121]. 
Finally, humoral immune responses were analyzed in a study of oral administration of  
liposome-entrapped BSA in carp (C. carpio). The BSA-containing liposomes were stable in carp bile 
and induced significant antibody responses against BSA in serum as well as in intestinal mucus and 
bile. BSA-specific antibody secreting lymphocytes were detected in the spleen and head kidney of 
immunized fish. In contrast, no serum antibody responses were observed when fish were orally 
immunized with BSA-containing unstable liposomes or BSA alone [122] (Table 2). 
2.5. Poly (Lactic-co-Glycolic Acid) (PLGA)  
PLGA, Poly (Lactic-co-Glycolic Acid) is a biodegradable polymer and probably the most extensively 
investigated carrier for drug delivery in mammals [130,131]. PLGA is a copolymer synthesized by two 
different monomers, lactic acid and glycolic acid. The forms of PLGA depend on the monomer ratio 
used during the polymerization process. PLGA nanoparticles (PLGA-NPs) are degraded by hydrolysis 
and the degradation time depends on the monomer ratio and on the molecular weight of the  
polymers [132]. The PLGA-NPs were approved for human use by the Food and Drug Administration 
(FDA, USA) and the European Medicines Agency (EMA), because they are highly biodegradable and 
biocompatible [133]. When the polymer is hydrolyzed the glycolic and lactic acid monomers are released 
and are eventually removed from the body through the citric acid cycle [134]. For this reason, there is 
minimal toxicity associated with the use of PLGA as a nanodelivery system since these components are 
present in different metabolic pathways. The most common PLGA-NPs preparation method used in fish 
is the double emulsion method [123–128] which is based on the dissolution of an appropriate amount of 
polymer (PLGA) in an organic solvent (oil phase) such as dichloromethane, chloroform or  
ethylacetate [135]. Hydrophobic drugs can be added directly to the oil phase, whereas hydrophilic drugs 
must be first emulsified with the polymer solution prior to the formation of particles [136]. Then, the 
solution is emulsified by the addition of an aqueous solution containing a surfactant or an emulsifying 
agent (e.g., polyvinyl alcohol). By reducing the pressure or by continuous stirring the organic solvent 
evaporates and this results in the formation of solid nanoparticles. The encapsulation efficiency and the 
particle size can be controlled by the solvent choice and the stirring rate [135]. 
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The internalization of PLGA-NPs by cells involves different uptake mechanisms. In mammals, the 
PLGA-NPs are able to avoid the endo-lysosomal system and are maintained in the cytoplasm. The 
uptake mechanisms of PLGA-NPs in teleosts is poorly understood and few published work have 
addressed this issue [118]. Despite this, it is known that nanoparticles of less than 500 nm in size are 
able to enter the bloodstream and subsequently they are cleared by phagocytes in the head kidney, 
spleen, and/or liver [137]. PLGA-NPs are highly versatile loading bioactive compounds. For 
applications in fish, γ-globulins from human blood, β-glucan [127,128], DNA vaccines [124–126] or 
the bacterial outer membrane complex [123] have been encapsulated (Table 2).  
2.5.1. Encapsulation of Bacterial Antigens in PLGA-NPs and -MPs 
PLGA-NPs were compared with polylactic acid-NPs (PLA-NPs), which also have good mechanical 
strength, to encapsulate the outer membrane complex from A. hydrophyla [138,139]. This complex 
consists mainly of lipopolysaccharide, phospholipids, and a group of outer membrane proteins. The 
encapsulation efficiency was higher in PLGA-NPs compared with PLA-NPs (59% and 44%, 
respectively) but the release in vitro was slower from PLA-NPs than from PLGA-NPs (50% at 24 h and 
4 h, respectively). This might be explained by the higher hydrophilic nature of the PLGA- compared to 
PLA-NPs. The non-specific and specific immunity were stimulated in L. rohita by both PLGA- and 
PLA-NPs and this at higher levels than the naked antigen (Table 2). Finally, in a challenge against  
A. hydrophyla, the PLA-vaccine provided higher levels of protection compared with the PLGA-vaccine 
(75% RPS and 55% RPS, respectively) and with the naked antigen (38% RPS) [123]. In addition, the 
encapsulation of the same antigen in PLGA-microparticles (PLGA-MPs) was evaluated [56]. These 
PLGA-MPs were studied in L. rohita administrated parenterally (Table 2). Encapsulation efficiency of 
PLGA-MPs was lower compared to PLGA-NPs (25% and 50%, respectively). Both the microparticles 
and the nanoparticles significantly stimulated non-specific (myeloperoxidase, respiratory burst activity, 
haemagglutination, etc.) and specific immune response parameters at similar levels at 21 and 42 days 
after vaccination. Finally, in a challenge study PLGA-NPs provided protection (55% RPS) against  
A. hydrophila infection, while no data was reported for PLGA-MPs [123].  
Oligodeoxynucleotides (ODNs) are short single-stranded synthetic DNA molecules that contain 
unmethylated CpG motifs. These motifs are highly abundant in bacterial DNA and extremely rare in 
vertebrates, and they are classified as a type of Pathogen Associated Molecular Pattern (PAMP).  
In mammals, they are recognized by Toll-like receptor 9 leading to strong immunostimulatory effects 
and also fish are able respond to CpG binding to TLR9 [140]. This antigen was encapsulated in 
PLGA/liposome-MPs and used to stimulate the immune system of E. bruneus using intraperitoneal 
injection [61] (Table 2). Superoxide dismutase, respiratory burst, and complement activity were mainly 
stimulated by the PLGA/Liposome microparticles. In contrast, the adaptive immune response and the 
specific V. alginolyticus serum antibody levels were significantly higher with the PLGA-MPs. Finally, 
the treatment with the PLGA-, Liposome- and PLGA/Liposome-MPs encapsulating ODNs provided 
good protection levels (78%, 83%, and 83% of RPS, respectively) against a V. alginolyticus  
infection [61] but they are not significantly different from the naked ODN (78% RPS).  
The alginate-MPs mentioned in section 2.1.1 were compared with PLGA-MPs as vehicles for the 
delivery of FKB from L. garvieae (Table 2). The PLGA-NPs provided similar protection levels than 
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alginate-FKB-LG (about 63% RPS at 30 days), but lower when compared with the conventional FKB 
vaccine intraperitoneally injected (95% RPS) [45]. 
Hølvold et al. [124] encapsulated in PLGA-NPs a plasmid containing the firefly luciferase gene under 
the control of the CMV-IEP promoter. Despite the fact that this formulation does not contain a specific 
bacterial antigen, the plasmid itself is from bacterial origin and acts as an immunostimulant (bacterial 
CpG). The PLGA-NPs showed a fast release of the plasmid (80% after 1 h), induced a significant 
increase in IL-1β and IFNα gene expression in muscle at the injection site in comparison with naked 
plasmid and stimulated TNFα expression in head kidney. The PLGA-NPs labeled with [125I]-fluorescein 
were detected until day 70 in trunk kidney, muscle and organ package (liver, heart, gastrointestinal tract 
and interstitial adipose tissue) [124]. The performance of these NPs was here also compared to MPs. The 
PLGA-MPs showed a lower release of antigen than the PLGA-NPs (49% at 1 h and an accumulative 
release of 69% at day 70; 81% at 1 h and an accumulative release of 96% at day 70, respectively). 
Additionally, PLGA-MPs had a higher retention than PLGA-NPs at the injection site, contributing to the 
onset of severe histopathological inflammation. This suggests that nanoparticles are more suited to avoid 
potential tissue damage. Both PLGA-MPs and PLGA-NPs showed better performance than naked 
plasmid DNA for the induction of pro-inflammatory and antiviral immune responses [124]. 
2.5.2. Encapsulation of Viral Antigens in PLGA-NPs and -MPs 
PLGA-NPs have been mainly used to encapsulate DNA vaccines aiming to protect against viral 
diseases. Lymphocystis Disease Virus (LCDV) infection is not lethal, but infected fish are more 
susceptible to secondary microbial infection [141]. The progression of the disease correlates with an 
increase in the presence of nodules. A plasmid coding for the major capsid protein (MCP) of LCDV 
was encapsulated in PLGA-NPs and PLGA-MPs and tested in P. olivaceus [125]. The encapsulation 
efficiency was 64% and full release (100%) was achieved after 60 h at pH 2.0 and after 90 h at pH 9.0. 
MCP gene expression was detected in gills, intestine, spleen, and kidney from 10 to 90 days after oral 
administration. Specific serum antibody titers against LCDV reached a maximum at 30 days  
post-administration. Importantly, in a challenge against LCDV, the presence of nodules was 
significantly lower in PLGA-vaccinated fish compared to naked DNA vaccinated fish (17% versus 
100%, respectively) [125]. Of note, Tian and coworkers showed that the encapsulation efficiency in 
PLGA microparticles was more stable than in the nanoparticle system (78%–88% and 64%–96%,  
respectively) [57,125]. PLGA-NPs and PLGA-MPs displayed similar performance except that the 
nanoparticles showed higher release characteristics. The study concluded that PLGA-MPs were also 
effective oral carriers for the transfer of plasmid DNA [57].  
Other PLGA-NPs containing a DNA vaccine against Infectious Haematopoetic Necrosis Virus 
(IHNV) were used to vaccinate O. mykiss (Table 2). In this case, the release of plasmid DNA was not 
clearly pH dependent, nor were there significant differences between the number of fish expressing the 
plasmid gene compared to the naked plasmid treatment. This PLGA-vaccine was also not able to 
confer protection against IHNV [126]. 
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2.5.3. Encapsulation of Other Antigens into PLGA-NPs and -MPs 
As mentioned above, PLGA-NPs allow maximal versatility in encapsulating molecules of different 
nature. Other representative examples of this are immunostimulants such as γ-globulins from human 
blood, β-glucan from L. hyperborea and hemocyanin from Limulus polyphemus (Table 2). Three 
different loaded PLGA-NPs (β-glucan, hemocyanin and both combined) were administrated by 
intraperitoneal injection in S. salar (Table 2). The gene expression profile showed that even PLGA-NPs 
alone induced a mild inflammatory response in S. salar having potential as an adjuvant in salmon 
vaccine [127]. In a subsequent study, the same group assessed different formulations of PLGA-NPs and 
-MPs at different monomer ratios. The release of the antigen was similar (around 10%) for all 
formulations, however the nanoparticles co-encapsulating γ-globulins and β-glucan induced the highest 
specific antibody response [128]. In another study, PLGA-MPs loaded with γ-globulins were also 
investigated in S. salar by oral administration. The encapsulation in PLGA-MPs allowed its stability in 
the stomach for longer periods of time, slowing down the passage into the intestine and increasing the 
levels of intact antigen reaching the blood stream. Also, the PLGA-MPs stimulated the antibody titer in 
serum but not in cutaneous mucus, gut mucus, or in bile [58]. 
Parasitic protozoa have developed sophisticated evasion mechanisms to evade the host’s innate 
immune defenses and currently, there are no anti-parasitic vaccines commercially available for farmed 
fish. A unique study aimed to design a specific delivery system for parasite disease prevention [59]. 
Formalin-killed parasite (i-antigen) from Uronema marimun, an opportunistic pathogen infecting 
flounder (P. olivaceus) and grouper (E. bruneus), was encapsulated into PLGA-MPs. The PLGA-MPs 
were administrated to E. bruneus by intraperitoneal injection and different innate immune response 
parameters such as respiratory burst activity, serum lysozyme activity, or complement activity were 
evaluated. All of them were stimulated by PLGA-MPs and were sustained from one to four weeks, 
whereas the treatment with the free i-antigen was detected only at week four and at lower levels. The 
specific i-antigen antibody levels were stimulated both by the free i-antigen and the PLGA-i-antigen, 
but again at higher levels by the PLGA-MPs [59]. Interestingly, the levels of protection from the 
loaded PLGA-MPs against U. marinum infection were notably high (only 20% of cumulative mortality 
after 30 days), but only slightly different from the empty PLGA-MPs or the free i-antigen [59].  
2.6. Other Nanodelivery Systems 
Although the amount of research done in mammals and fish is not comparable, there exists a large 
effort to discover new nanodelivery systems in teleost to cover the different needs for the prevention of 
diseases in aquaculture. Here we mention two additional approaches aiming to develop new 
nanomaterials for in vivo delivery in fish: calcium phosphate nanoparticles (CaP-NPs) [119] and solid 
lipid nanoparticles (SL-NPs) [129].  
Calcium phosphate is a natural, inorganic, and biocompatible material. CaP-NPs are synthesized 
using different methods such as mechanochemical synthesis, combustion preparation, wet chemistry 
techniques, and others [142]. CaP-NPs can be produced in different morphologies, such as spheres, 
plate-like crystals, needles, or blades [142,143], however, the size and the stability of CaP-NPs are 
very difficult to control [143]. CaP-NPs are a potential nanodelivery system due to their high 
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bioactivity, biocompatibility, biodegradability and strong adsorption ability under physiological 
conditions. In mammals, they have been used as nanodelivery system for drugs, vectors, antibacterial 
agents, or as a vaccine adjuvant [142]. In L. rohita CaP-NPs loaded with the S-layer from  
A. hydrophila was assessed by intraperitonal injection (Table 2). The non-specific immune responses 
(superoxide dismutase, myeloperoxidase, respiratory burst, etc.) and the specific immune response 
(antibody titers) were stimulated and detected at 21, 42, and 63 days post-vaccination. When fish were 
challenged with A. hydrophila, loaded CaP-NPs were able to provide good levels of protection 15 days 
post-vaccination (97% RPS) with a significant difference in comparison with non-encapsulated S-layer 
(13% RPS), but with similar level (94% of RPS) when compared with CaP-NPs with only Freund`s 
incomplete adjuvant [119].  
Solid lipid nanoparticles are produced in solution using solid lipidic materials with surfactants that 
confer stability and co-surfactants that confer specific ligand properties [144]. SL-NPs can be prepared 
by different techniques, such as high-pressure homogenization, high-shear mixing, ultrasound, or 
solvent emulsification/evaporation methods [143,145]. Additionally, SL-NPs present a range of 
characteristic advantages, such as biocompatibility, non-toxicity, high bioavailability, high-antigen 
loading ability, controlled release, physical stability, and protection of encapsulated antigens. Finally, 
SL-NPs can be easily scaled-up for industrial purposes [145,146]. A preliminary in vitro characterization 
of SL-NPs was performed in fish [129] (Table 2). The loaded SL-NPs had a mean diameter of  
235–335 nm depending on the amount of cargo, with a net surface charge between −12.5 and −16.5 
mV. These nanoparticles were loaded with a fluorescent molecule (6-Coumarin) and were tested for 
uptake and toxicity in a cell line (SAF-1) and in leukocyte primary cell culture of S. aurata head 
kidney. Release of 6-Coumarin from SL-NPs was around 1% over the course of 48 h at 22 °C and both 
the cell line and the primary leukocytes were able to internalize these SL-NPs without affecting the cell 
viability. SL-NPs internalization was dose- and time-dependent. The uptake in SAF-1 cells decreased 
over time indicating that the SL-NPs in SAF-1 cells are likely processed in the endolysosomal 
compartment, while the fluorescent signal was stable over the time in primary leukocytes [129].  
3. Discussion 
Nowadays there is a large variety of materials that can be used as delivery systems for 
vaccine/immunostimulant administration in fish. This diversity provides a wide range of options to 
respond to the high number of different farmed species and the challenge to achieve a good health 
status in the presence of different potentially harmful microorganisms. However, the study of 
nanoparticles for aquacultural use is still in its early stage. Research shows variable efficiency of 
protection depending on the nature of the nanomaterials, the method to produce the nanoparticles, the 
antigens encapsulated or the fish species assessed. Often there is a lack of information about the 
manufacturing process as well as the physico-chemical characteristics of the nanoparticles and the 
properties of the antigens after the encapsulation process, hampering a correct analysis and comparison 
between delivery systems. For instance, not all publications mention the size of the particles, the 
efficiency of encapsulation or the release of the antigens in in vitro conditions (see Tables 1 and 2).  
In many cases, the starting point is the “recycling” of particles for mammalian use that are applied 
directly in fish, without considering the evident differences between mammals and fish. The researcher 
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working on fish health should make a strong effort to design or adapt nanoparticles in order to reach 
optimal compatibility with the fish characteristics. However, this is difficult because the fish immune 
system has several differences with the mammalian immune system regarding cell types, cell biology, 
tissues involved in immune response, etc. Also, the fish immune system is not well known in many 
aspects such as how the adaptive system memory works, which cell types are involved or the role of 
mucosal immunity. 
In general, the use of microparticles is more frequent than the use of nanoparticles even when the 
surface area/volume ratio is much more advantageous in nanoparticles. An explanation of this is that 
some materials are not easy to manipulate in the nanosize range or there are not protocols to nanosize 
such materials. An example is alginate that has been mainly used to produce microparticles and only 
recently has it started to be used to produce sub-200 nm particles [147]. Again, the characterization of 
the manufactured nanoparticles should be detailed in the publications in order to compare between the 
administration routes, the adjuvant properties, the potential degradation of the loaded compound, the 
efficacy of the system protecting against infection, and the targeted cells or tissues. Different fish 
species have different responses to vaccination [148] and this fact should be considered when choosing 
an encapsulation system because they may not be transferable from one species to another. 
Additionally, the encapsulated antigens modify the physico-chemical characteristics of the nanodelivery 
system so that the results of the assays on stability, size, surface charge, and organ biodistribution 
cannot be extrapolated from one molecule to another using the same encapsulating particle. Similarly, 
the characteristics of the antigen can be changed when it is encapsulated, and thus the functional 
structure, stability, and immunogenicity of the antigen need to be verified. For example, the size and 
the surface charge are extremely important for interaction with cells and should be characterized in the 
loaded system because they can change easily [118]. Of note, in some cases the encapsulation did not 
provide any protection [40] or did not improve the protection with respect to conventional 
immunoprotective therapies [55]. Overall, the administration of nanoparticles by intraperitoneal 
injection achieves good protection levels against infections while the oral administration is at this 
moment less efficient. One of the exceptions is the system developed with alginate or chitosan to 
encapsulate DNA vaccines [41,42]. DNA vaccines are still under development and only one 
commercial vaccine has been licensed in Canada. They are the most promising tools to fight viral 
infections and thus, the development of novel encapsulation systems to improve their administration 
and the efficiency is very important. Several new nanomaterials such as carbon nanotubes or solid lipid 
NP are still in the early steps of development but have shown promising results. For example, CNTs 
have been very effective for encapsulating a DNA vaccine and to confer protection against infection 
even at low DNA concentrations [73]. It is important to mention that in some studies, the adjuvant 
effect of the nanodelivery system is almost as potent as the loaded antigen itself. The adjuvant effect of 
the system itself has been extensively reported in mammals (e.g., liposomes) and it is also clearly 
observed in some fish species [124] but not in others [23].  
Also an important point that should be taken into consideration is the final cost of the encapsulation 
system for industrial production. Some of the systems developed under research conditions are expensive 
and may not be affordable for the fish farmers. Finally, all of the nanodelivery systems included in this 
review have been characterized as non-toxic for cells (in vitro viability assays) and similarly in vivo. 
Biology 2015, 4 686 
 
 
However, the toxicity of nanomaterials and, more importantly, the toxicity of the nanomaterial degradation 
products that could be detected in water should be addressed carefully [149,150]. 
4. Conclusions 
Altogether, nano-encapsulation is a very promising strategy with a potential to substantially improve 
the development of effective vaccines for farmed fish. The research on the delivery of viral vaccines 
using nanoparticles will be the more important milestone in fish vaccinology. In this context, more 
traditional biomaterials such as alginate and chitosan have shown good results but new materials such 
as CNTs or solid lipid NP could improve the delivery of DNA vaccines. More research is still needed 
to specifically design encapsulation systems adapted to the fish immune system and to decipher the 
basis of the fish immune system.  
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